Business
CorMedix Completes Sale of $5.4 Million of NOL Tax Benefits Through New Jersey Economic Development Authority Program
BERKELEY HEIGHTS, N.J., April 17, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American:CRMD), a biopharmaceutical company focused on developing and
About this update from Cormedix Inc.
[{"type":"text","content":"BERKELEY HEIGHTS, N.J., April 17, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed the previously announced sale of $5.4 million of NOL tax benefits to two unrelated, profitable New Jersey corporations through the New Jersey Economic Development Authority's New Jersey Technology Business Tax Certificate Transfer program for State Fiscal Year 2018. As a result, the Company has received approximately $5.1 million in cash from the sale of these NOL tax benefits.\"We are pleased to have closed on this transaction,\" said Khoso Baluch, CorMedix CEO. \"The funding bolsters our cash runway as we continue to move the Neutrolin® development program forward.\"The New Jersey Technology Business Tax Certificate Transfer (NOL) program enables qualified, unprofitable NJ-based technology or biotechnology companies with fewer than 225 U.S. employees (including parent company and all subsidiaries) to sell a percentage of net operating losses and research and development (R&D) tax credits to unrelated profitable corporations. NOLs and R&D tax credits may be sold for at least 80 percent of their value, up to a maximum lifetime benefit of $15 million per business. This allows qualifying technology and biotechnology companies with NOLs to turn their tax losses and credits into cash proceeds to fund growth and operations, including research and development or other allowable expenditures.About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in Phase 3 development for patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides t...